Opus Genetics (IRD) Change in Receivables (2022 - 2026)
Opus Genetics (IRD) posted quarterly Change in Receivables of -$264000.0 for Q1 2026, up 45.34% year-over-year from -$181641.0 in Q1 2025, and up 71.34% quarter-over-quarter from -$921000.0 in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Change in Receivables (2022 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Change in Receivables for 5 consecutive years, with -$264000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 45.34% year-over-year to -$264000.0; the TTM figure through Mar 2026 stood at -$1.3 million (down 216.7% YoY), while the FY2025 annual figure was -$1.6 million, down 159.46% from the prior year.
- Change in Receivables climbed to -$264000.0 in Q1 2026 per IRD's latest filing, from -$921000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $10.0 million in Q3 2023 and bottomed at -$9.2 million in Q4 2023.
- Historically, Change in Receivables has averaged $123642.9 across 5 years, with a median of $27500.0 in 2025.
- Annual changes were most pronounced in 2023 — Change in Receivables sank 809.24% — and 2025, when it soared 156.36%.
- Opus Genetics' Change in Receivables stood at $1.3 million in 2022, then tumbled by 809.24% to -$9.2 million in 2023, then jumped by 118.53% to $1.7 million in 2024, then sank by 153.99% to -$921000.0 in 2025, then soared by 71.34% to -$264000.0 in 2026.
- Business Quant data shows IRD's Change in Receivables at -$264000.0 in Q1 2026, -$921000.0 in Q4 2025, and -$483000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | -690,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -690,000.00 |
| Mar 31, 2026 | -264,000.00 |
| Dec 31, 2025 | -921,000.00 |
| Sep 30, 2025 | -483,000.00 |
| Jun 30, 2025 | 319,000.00 |
| Mar 31, 2025 | -483,000.00 |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 499,000.00 |
| Jun 30, 2024 | -566,000.00 |
| Mar 31, 2024 | 998,000.00 |
| Dec 31, 2023 | -9.21 Mn |
| Sep 30, 2023 | 10.00 Mn |
| Jun 30, 2023 | -2.70 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 1.30 Mn |